
Cecile Mather
Advertisement
Articles by Cecile Mather



24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
2
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
3
Radiation Oncology Trials You May Have Missed at ASCO 2026
4
Camizestrant Extends PFS and PFS2 in ESR1-Mutated Advanced Breast Cancer
5
